Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study

To investigate whether a risk score for prostate cancer (PCa) lifetime risk can be used to optimise triaging of patients with a negative prostate biopsy, but under sustained suspicion of PCa.

[1]  V. Novack,et al.  The use of prostate specific antigen density to predict clinically significant prostate cancer , 2020, Scientific Reports.

[2]  S. Lundbye-Christensen,et al.  Regression models for interval censored data using parametric pseudo-observations , 2020, BMC Medical Research Methodology.

[3]  S. Skeie,et al.  Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system – the Stavanger experience , 2020, Scandinavian journal of primary health care.

[4]  Prostate Imaging-Reporting and Data System , 2020, Definitions.

[5]  K. D. Sørensen,et al.  The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial , 2020, PLoS medicine.

[6]  R. V. D. van den Bergh,et al.  Hereditary prostate cancer - Primetime for genetic testing? , 2019, Cancer treatment reviews.

[7]  D. Margolis,et al.  Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. , 2019, European urology.

[8]  NICE Guidance – Prostate cancer: diagnosis and management , 2019, BJU international.

[9]  Jianfeng Xu,et al.  Current progress and questions in germline genetics of prostate cancer , 2018, Asian journal of urology.

[10]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[11]  K. D. Sørensen,et al.  Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci , 2018, Nature Genetics.

[12]  Martin Eklund,et al.  Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer , 2017, Prostate Cancer and Prostatic Diseases.

[13]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[14]  O. Andreassen,et al.  Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts , 2018, British Medical Journal.

[15]  Leigh H. Simmons,et al.  Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection. , 2017, The Medical clinics of North America.

[16]  D. Parekh,et al.  Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy. , 2017, Urology.

[17]  Mahul B Amin,et al.  Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2017, The American journal of surgical pathology.

[18]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[19]  B. Vainer,et al.  Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. , 2017, The Lancet. Oncology.

[20]  Martin Eklund,et al.  The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing. , 2016, European urology focus.

[21]  R. Eeles,et al.  Genetic predisposition to prostate cancer. , 2016, British medical bulletin.

[22]  K. D. Sørensen,et al.  Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness , 2016, BJU international.

[23]  Martin Eklund,et al.  Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. , 2015, The Lancet. Oncology.

[24]  Peter Kraft,et al.  A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer , 2014, Nature Genetics.

[25]  H. Woo,et al.  Current Status of Biomarkers for Prostate Cancer , 2013, International journal of molecular sciences.

[26]  E. Bleecker,et al.  Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. , 2012, European urology.

[27]  Thomas Hambrock,et al.  Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. , 2012, European urology.

[28]  Yipeng Hu,et al.  A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)‐biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy , 2012, BJU international.

[29]  D Andrew Loblaw,et al.  Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. D. de Koning,et al.  Quality-of-life effects of prostate-specific antigen screening. , 2012, The New England journal of medicine.

[31]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[32]  Sadhna Verma,et al.  Imaging-guided prostate biopsy: conventional and emerging techniques. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[33]  Suzanne Chambers,et al.  Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study , 2011, Nature Genetics.

[34]  D. Neal.  PSA testing for prostate cancer improves survival--but can we do better? , 2010, The Lancet. Oncology.

[35]  Thomas Hambrock,et al.  Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. , 2010, The Journal of urology.

[36]  O. Bratt.  What should a urologist know about hereditary predisposition to prostate cancer? , 2007, BJU international.

[37]  C. Padovani,et al.  Complications and risk factors in transrectal ultrasound-guided prostate biopsies. , 2006, Sao Paulo medical journal = Revista paulista de medicina.

[38]  Holly T. Sullivan,et al.  Clinical staging of prostate cancer: a computer‐simulated study of transperineal prostate biopsy , 2005, BJU international.

[39]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[40]  G. Cable,et al.  Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. , 2003, The Journal of the American Board of Family Practice.

[41]  A. Zlotta,et al.  Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. , 2001, The Journal of urology.

[42]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[43]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[44]  Ming Wang,et al.  PSAD Test in the Diagnosis of Prostate Cancer: a Meta-Analysis. , 2017, Clinical laboratory.

[45]  D. Margolis,et al.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. , 2016, European urology.

[46]  Ali Amin Al Olama,et al.  The genetic epidemiology of prostate cancer and its clinical implications , 2014, Nature Reviews Urology.